CA2501717C - Use of epothilone derivatives for the treatment of hyperparathyroidism - Google Patents
Use of epothilone derivatives for the treatment of hyperparathyroidism Download PDFInfo
- Publication number
- CA2501717C CA2501717C CA2501717A CA2501717A CA2501717C CA 2501717 C CA2501717 C CA 2501717C CA 2501717 A CA2501717 A CA 2501717A CA 2501717 A CA2501717 A CA 2501717A CA 2501717 C CA2501717 C CA 2501717C
- Authority
- CA
- Canada
- Prior art keywords
- parathyroid
- hyperparathyroidism
- hydrogen
- recurrent
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000003883 epothilone derivatives Chemical class 0.000 title claims abstract description 27
- 201000002980 Hyperparathyroidism Diseases 0.000 title claims abstract description 26
- 241001465754 Metazoa Species 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 26
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- 230000002085 persistent effect Effects 0.000 claims description 17
- 230000000306 recurrent effect Effects 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 206010033964 Parathyroid tumour benign Diseases 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 201000003686 parathyroid adenoma Diseases 0.000 claims description 13
- 201000003913 parathyroid carcinoma Diseases 0.000 claims description 13
- 208000014643 parathyroid gland adenoma Diseases 0.000 claims description 13
- 208000017954 parathyroid gland carcinoma Diseases 0.000 claims description 13
- 208000025061 parathyroid hyperplasia Diseases 0.000 claims description 12
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 11
- 230000000148 hypercalcaemia Effects 0.000 claims description 11
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 11
- -1 methoxy, ethoxy, amino, methylamino, dimethylamino Chemical group 0.000 claims description 10
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 10
- 230000003442 weekly effect Effects 0.000 claims description 7
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 208000003200 Adenoma Diseases 0.000 claims description 3
- 206010001233 Adenoma benign Diseases 0.000 claims description 3
- 206010020707 Hyperparathyroidism primary Diseases 0.000 claims description 3
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 claims description 3
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims description 3
- 206010020718 hyperplasia Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 9
- 150000001875 compounds Chemical class 0.000 description 20
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 16
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 14
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 8
- 230000002491 angiogenic effect Effects 0.000 description 6
- 208000002458 carcinoid tumor Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 230000006427 angiogenic response Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 230000001142 anti-diarrhea Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229930013356 epothilone Natural products 0.000 description 3
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 229940125714 antidiarrheal agent Drugs 0.000 description 2
- 239000003793 antidiarrheal agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 150000003951 lactams Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000028198 tertiary hyperparathyroidism Diseases 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 0 CC(C(C)c1c[s]c(*)n1)[C@](C*[C@](C)(*)CCC[C@](C)[C@]([C@](C)C(C(C)(C)[C@](C1)O)=O)O)*C1O Chemical compound CC(C(C)c1c[s]c(*)n1)[C@](C*[C@](C)(*)CCC[C@](C)[C@]([C@](C)C(C(C)(C)[C@](C1)O)=O)O)*C1O 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- BEFZAMRWPCMWFJ-JRBBLYSQSA-N Epothilone C Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C BEFZAMRWPCMWFJ-JRBBLYSQSA-N 0.000 description 1
- XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000002419 Motilin Human genes 0.000 description 1
- 101800002372 Motilin Proteins 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 description 1
- 229960000782 bismuth subsalicylate Drugs 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000009643 clonogenic assay Methods 0.000 description 1
- 231100000096 clonogenic assay Toxicity 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- BEFZAMRWPCMWFJ-UHFFFAOYSA-N desoxyepothilone A Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC=CCC1C(C)=CC1=CSC(C)=N1 BEFZAMRWPCMWFJ-UHFFFAOYSA-N 0.000 description 1
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UFIVBRCCIRTJTN-UHFFFAOYSA-N difenoxin Chemical compound C1CC(C(=O)O)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 UFIVBRCCIRTJTN-UHFFFAOYSA-N 0.000 description 1
- 229960005493 difenoxin Drugs 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- BEFZAMRWPCMWFJ-QJKGZULSSA-N epothilone C Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 BEFZAMRWPCMWFJ-QJKGZULSSA-N 0.000 description 1
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 239000008414 paregoric Substances 0.000 description 1
- 229940069533 paregoric Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41859202P | 2002-10-15 | 2002-10-15 | |
| US60/418,592 | 2002-10-15 | ||
| PCT/IB2003/004514 WO2004035050A1 (en) | 2002-10-15 | 2003-10-13 | Use of epothilone derivatives for the treatment of hyperparathyroidism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2501717A1 CA2501717A1 (en) | 2004-04-29 |
| CA2501717C true CA2501717C (en) | 2012-09-18 |
Family
ID=32107949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2501717A Expired - Fee Related CA2501717C (en) | 2002-10-15 | 2003-10-13 | Use of epothilone derivatives for the treatment of hyperparathyroidism |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20060142354A1 (enExample) |
| EP (1) | EP1553938B1 (enExample) |
| JP (1) | JP4672368B2 (enExample) |
| CN (1) | CN1297269C (enExample) |
| AT (1) | ATE350034T1 (enExample) |
| AU (1) | AU2003267751A1 (enExample) |
| BR (1) | BR0315293A (enExample) |
| CA (1) | CA2501717C (enExample) |
| CY (1) | CY1106385T1 (enExample) |
| DE (1) | DE60310975T2 (enExample) |
| DK (1) | DK1553938T3 (enExample) |
| ES (1) | ES2279139T3 (enExample) |
| PT (1) | PT1553938E (enExample) |
| SI (1) | SI1553938T1 (enExample) |
| WO (1) | WO2004035050A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| DK1767535T3 (da) | 2002-08-23 | 2010-04-12 | Sloan Kettering Inst Cancer | Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2106553T5 (es) * | 1993-07-19 | 2008-02-16 | Angiotech Pharmaceuticals, Inc. | Composiciones anti-angiogenicas y metodos de uso. |
| PT1367057E (pt) * | 1996-11-18 | 2008-12-04 | Biotechnolog Forschung Gmbh | Epotilonas e e f |
| US6380394B1 (en) * | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
| PL201329B1 (pl) * | 1998-02-05 | 2009-03-31 | Novartis Ag | Preparat farmaceutyczny w postaci koncentratu infuzyjnego |
| US6302838B1 (en) * | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
-
2003
- 2003-10-13 ES ES03748446T patent/ES2279139T3/es not_active Expired - Lifetime
- 2003-10-13 US US10/530,855 patent/US20060142354A1/en not_active Abandoned
- 2003-10-13 JP JP2004544592A patent/JP4672368B2/ja not_active Expired - Fee Related
- 2003-10-13 AT AT03748446T patent/ATE350034T1/de active
- 2003-10-13 DE DE60310975T patent/DE60310975T2/de not_active Expired - Lifetime
- 2003-10-13 EP EP03748446A patent/EP1553938B1/en not_active Expired - Lifetime
- 2003-10-13 AU AU2003267751A patent/AU2003267751A1/en not_active Abandoned
- 2003-10-13 PT PT03748446T patent/PT1553938E/pt unknown
- 2003-10-13 CA CA2501717A patent/CA2501717C/en not_active Expired - Fee Related
- 2003-10-13 SI SI200330741T patent/SI1553938T1/sl unknown
- 2003-10-13 CN CNB200380101281XA patent/CN1297269C/zh not_active Expired - Fee Related
- 2003-10-13 DK DK03748446T patent/DK1553938T3/da active
- 2003-10-13 WO PCT/IB2003/004514 patent/WO2004035050A1/en not_active Ceased
- 2003-10-13 BR BR0315293-6A patent/BR0315293A/pt not_active IP Right Cessation
-
2007
- 2007-03-15 CY CY20071100363T patent/CY1106385T1/el unknown
-
2011
- 2011-03-01 US US13/037,989 patent/US20110152329A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1297269C (zh) | 2007-01-31 |
| PT1553938E (pt) | 2007-03-30 |
| WO2004035050A1 (en) | 2004-04-29 |
| ATE350034T1 (de) | 2007-01-15 |
| HK1080768A1 (en) | 2006-05-04 |
| DE60310975T2 (de) | 2007-07-12 |
| AU2003267751A1 (en) | 2004-05-04 |
| DE60310975D1 (de) | 2007-02-15 |
| EP1553938B1 (en) | 2007-01-03 |
| DK1553938T3 (da) | 2007-03-26 |
| US20060142354A1 (en) | 2006-06-29 |
| JP4672368B2 (ja) | 2011-04-20 |
| BR0315293A (pt) | 2005-08-30 |
| ES2279139T3 (es) | 2007-08-16 |
| CY1106385T1 (el) | 2011-10-12 |
| JP2006504751A (ja) | 2006-02-09 |
| CA2501717A1 (en) | 2004-04-29 |
| SI1553938T1 (sl) | 2007-06-30 |
| US20110152329A1 (en) | 2011-06-23 |
| EP1553938A1 (en) | 2005-07-20 |
| CN1703217A (zh) | 2005-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8268837B2 (en) | Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia | |
| US20090246172A1 (en) | Compositions comprising epothilones and their use for the treatment of carcinoid syndrome | |
| US20110033458A1 (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
| JP3832229B2 (ja) | フェニルエテンスルホンアミド誘導体含有医薬 | |
| EP1503756B1 (en) | Epothilone derivative for the treatment of hepatoma and other cancer diseases | |
| US20110152329A1 (en) | Use of Epothilone Derivatives for the Treatment of Hyperparathyroidism | |
| HK1080768B (en) | Use of epothilone derivatives for the treatment of hyperparathyroidism | |
| AU2003223958B2 (en) | Combinations comprising epothilone derivatives and alkylating agents | |
| AU2002366531B2 (en) | Compositions comprising epothilones and their use for the treatment of carcinoid syndrome | |
| AU2007200677B2 (en) | Combinations comprising epothilones and anti-metabolites | |
| HK1069983B (en) | Compositions comprising epothilones and their use for the treatment of the carcinoid syndrome | |
| ZA200404013B (en) | Compositions comprising epothilones and their use for the treatment of carcinoid syndrome. | |
| AU2007200588A1 (en) | Compositions comprising epothilones and their use for the treatment of carcinoid syndrome | |
| AU2008200068A1 (en) | Combinations comprising epothilones and pharmaceutical uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20141014 |